Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Implementing Hybrid Work Policy In January

Executive Summary

Agency employees will have on-site, telework and remote possibilities, but options will depend on the center, office and job duties.

You may also be interested in...



Ban On US FDA User Fee Spending For Certain Facility Costs Forced Budget Shift

Soon-to-be enacted limitation on user fees means building maintenance and other expenses must be paid with non-user fee dollars. The issue was thought to be a significant operational impediment, but the most recent appropriations bill provided some relief.

US FDA Opens OTP Director Search Again

The new job notice offers a top salary, but also invites questions about the candidate pool attracted by the original solicitation.

CBER’s New Home For Gene Therapies: OTAT Changes To OTP But Leadership Questions Remain

US FDA has not named permanent heads of several offices within the new Office of Therapeutic Products, the only super office in the Center for Biologics Evaluation and Research.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147353

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel